SCHEMBL2399342

SCHEMBL2399342

COc1ccc(C(=O)N2CCC3(CC2)CC(C(=O)NCc2ccccc2)=NO3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.52
TSHR P16473 3/20 0.52
DHODH Q02127 2/20 0.49
CYP3A4 P08684 3/20 0.48
ALDH1A1 P00352 4/20 0.48
USP2 O75604 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPK8 P45983 1/20 0.47
MAPK10 P53779 1/20 0.47
CYP2C9 P11712 3/20 0.47
MAPK1 P28482 1/20 0.47
HIF1A Q16665 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
POLB P06746 1/20 0.46
CDK1 P06493 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404875 0.88 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2KMT2AMAPK8MAPK10
SCHEMBL2400949 0.88 CYP3A4 (0.50) CYP2D6TSHRCYP3A4ALDH1A1USP2
SCHEMBL6410565 0.85 CYP2D6 (0.51) CYP2D6TSHRDHODHCYP3A4ALDH1A1
SCHEMBL2399119 0.85 POLB (0.44) CYP2D6TSHRCYP3A4ALDH1A1USP2
SCHEMBL2400307 0.83 CYP2D6 (0.44) CYP2D6MEN1KMT2AMAPK1CYP1A2
SCHEMBL2402307 0.83 POLB (0.56) CYP2D6TSHRCYP3A4ALDH1A1USP2
SCHEMBL2400778 0.82 HTR1A (0.52)
SCHEMBL2400325 0.81 GPR119 (0.54) SMN1; SMN2MEN1KMT2ALMNAJAK1
SCHEMBL2577819 0.80 NAMPT (0.50) TSHRCYP3A4ALDH1A1SMN1; SMN2MAPK8
SCHEMBL2400339 0.80 ALOX15 (0.42) SMN1; SMN2MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US claimed
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP claimed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US claimed
US-8557796-B2 Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2013-10-15 US disclosed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods SULT1E1, CYP4B1, CYP3A4 CYP2D6 37/4885TSHR 2319/4885DHODH 297/4885
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 CYP2D6 27/4885TSHR 1894/4885DHODH 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.